28058039|t|Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients
28058039|a|Hepatitis C virus (HCV) is a significant global public health problem with >185 million infections worldwide. A series of genome-wide association studies (GWAS) has identified IL-28B polymorphisms as a predictor of sustained virologic response (SVR), as well as spontaneous clearance in chronic HCV genotype 1 patients. The objective of this work was to evaluate the prevalence of IL-28B rs12979860 and rs8099917 polymorphisms in Cuban chronic HCV patients. The study cohort included 73 chronic HCV patients treated with concomitant administration of CIGB-230 and nonpegylated IFN-α plus ribavirin (non-pegIFN-α / R) antiviral therapy. The genotype distribution of IL-28B rs12979860CC, - CT, and - TT was 29, 41, and 30%, respectively, and the distribution for rs8099917TT, - TG, and - GG was 63, 31, and 5%, respectively. The allele frequencies for rs12979860C and - T alleles were 51 and 49%, respectively, and for rs8099917G and - T alleles, the values were 21 and 79%, respectively. SVR rates were 55, 42, and 35% for rs12979860CC, - CT, and - TT, respectively, and 52, 30, and 25% for rs8099917TT, - GT, and - GG, respectively. The combined assessment of both single nucleotide polymorphisms (SNPs) resulted in 3 major genotypes (rs12979860CC / rs8099917TT, rs12979860CT / rs8099917TT, and rs12979860CT / rs8099917GG) with a frequency of 30.1, 21.9, and 20.5%, respectively. In patients with heterozygous variant rs12979860CT, the additional genotyping of rs8099917 contributed to increase the SVR rate. It is concluded that in Cuban HCV - infected patients, the responder homogeneous variant rs8099917TT is the most frequent genotype. The simultaneous genotyping of 2 IL-28B SNPs could improve the prediction of SVR contributing to better therapeutic decisions and treatment management.
28058039	0	10	Assessment	T058	UMLS:C0220825
28058039	14	19	IL-28	T017	UMLS:C1425475
28058039	36	45	rs8099917	T017	UMLS:C0678941
28058039	46	59	Polymorphisms	T038	UMLS:C0032529
28058039	65	71	Cohort	T098	UMLS:C0599755
28058039	75	80	Cuban	T098	UMLS:C1553379
28058039	81	104	Chronic HCV Genotype 1b	T038	UMLS:C4049394
28058039	114	131	Hepatitis C virus	T005	UMLS:C0220847
28058039	133	136	HCV	T005	UMLS:C0220847
28058039	202	212	infections	T038	UMLS:C3714514
28058039	213	222	worldwide	T098	UMLS:C2700280
28058039	236	267	genome-wide association studies	T062	UMLS:C2350277
28058039	269	273	GWAS	T062	UMLS:C2350277
28058039	290	296	IL-28B	T017	UMLS:C1425475
28058039	297	310	polymorphisms	T038	UMLS:C0032529
28058039	329	357	sustained virologic response	T033	UMLS:C4050171
28058039	359	362	SVR	T033	UMLS:C4050171
28058039	401	423	chronic HCV genotype 1	T038	UMLS:C4049394
28058039	438	447	objective	T170	UMLS:C0018017
28058039	468	476	evaluate	T058	UMLS:C0220825
28058039	517	526	rs8099917	T017	UMLS:C0678941
28058039	527	540	polymorphisms	T038	UMLS:C0032529
28058039	544	549	Cuban	T098	UMLS:C1553379
28058039	558	561	HCV	T005	UMLS:C0220847
28058039	609	612	HCV	T005	UMLS:C0220847
28058039	622	634	treated with	T058	UMLS:C0332293
28058039	647	661	administration	T058	UMLS:C1533734
28058039	665	673	CIGB-230	T103	UMLS:C3851847
28058039	678	696	nonpegylated IFN-α	T103	UMLS:C0002199
28058039	702	711	ribavirin	T103	UMLS:C0035525
28058039	713	725	non-pegIFN-α	T103	UMLS:C0002199
28058039	728	729	R	T103	UMLS:C0035525
28058039	731	748	antiviral therapy	T058	UMLS:C0280274
28058039	779	798	IL-28B rs12979860CC	T017	UMLS:C0678941
28058039	802	804	CT	T017	UMLS:C0678941
28058039	812	814	TT	T017	UMLS:C0678941
28058039	875	886	rs8099917TT	T017	UMLS:C0678941
28058039	890	892	TG	T017	UMLS:C0678941
28058039	900	902	GG	T017	UMLS:C0678941
28058039	964	975	rs12979860C	T017	UMLS:C0678941
28058039	982	983	T	T017	UMLS:C0678941
28058039	984	991	alleles	T017	UMLS:C0002085
28058039	1031	1041	rs8099917G	T017	UMLS:C0678941
28058039	1048	1049	T	T017	UMLS:C0678941
28058039	1050	1057	alleles	T017	UMLS:C0002085
28058039	1101	1104	SVR	T033	UMLS:C4050171
28058039	1136	1148	rs12979860CC	T017	UMLS:C0678941
28058039	1152	1154	CT	T017	UMLS:C0678941
28058039	1162	1164	TT	T017	UMLS:C0678941
28058039	1204	1215	rs8099917TT	T017	UMLS:C0678941
28058039	1219	1221	GT	T017	UMLS:C0678941
28058039	1229	1231	GG	T017	UMLS:C0678941
28058039	1260	1270	assessment	T058	UMLS:C0220825
28058039	1279	1310	single nucleotide polymorphisms	T082	UMLS:C0752046
28058039	1312	1316	SNPs	T082	UMLS:C0752046
28058039	1349	1361	rs12979860CC	T017	UMLS:C0678941
28058039	1364	1375	rs8099917TT	T017	UMLS:C0678941
28058039	1377	1389	rs12979860CT	T017	UMLS:C0678941
28058039	1392	1403	rs8099917TT	T017	UMLS:C0678941
28058039	1409	1421	rs12979860CT	T017	UMLS:C0678941
28058039	1424	1435	rs8099917GG	T017	UMLS:C0678941
28058039	1524	1531	variant	T017	UMLS:C0678941
28058039	1532	1544	rs12979860CT	T017	UMLS:C0678941
28058039	1561	1571	genotyping	T058	UMLS:C3178894
28058039	1575	1584	rs8099917	T017	UMLS:C0678941
28058039	1613	1616	SVR	T033	UMLS:C4050171
28058039	1647	1652	Cuban	T098	UMLS:C1553379
28058039	1653	1656	HCV	T005	UMLS:C0220847
28058039	1659	1667	infected	T033	UMLS:C0439663
28058039	1682	1691	responder	T033	UMLS:C0919876
28058039	1704	1711	variant	T017	UMLS:C0678941
28058039	1712	1723	rs8099917TT	T017	UMLS:C0678941
28058039	1772	1782	genotyping	T058	UMLS:C3178894
28058039	1788	1794	IL-28B	T017	UMLS:C1425475
28058039	1795	1799	SNPs	T082	UMLS:C0752046
28058039	1806	1813	improve	T033	UMLS:C0184511
28058039	1832	1835	SVR	T033	UMLS:C4050171
28058039	1871	1880	decisions	T038	UMLS:C0679006
28058039	1885	1905	treatment management	T058	UMLS:C0030677